ClinVar Miner

Submissions for variant NM_000046.5(ARSB):c.753C>G (p.Tyr251Ter)

dbSNP: rs765711776
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000579253 SCV000680732 pathogenic not provided 2019-05-01 criteria provided, single submitter clinical testing Not observed in large population cohorts (Lek et al., 2016); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 30118150, 28914427, 23430861, 27629047, 24798265, 31009684, 29620724)
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova RCV000677594 SCV000803111 pathogenic Mucopolysaccharidosis type 6 2018-01-01 criteria provided, single submitter curation Nonsense variant (PVS1); In vitro functional studies supportive of a damaging effect on the gene product (low to no ARSB activity in homozygotes; PS3); Absent from GnomAD (PM2); Reputable source identifies as pathogenic (PP5)
Invitae RCV000677594 SCV000937682 pathogenic Mucopolysaccharidosis type 6 2018-08-11 criteria provided, single submitter clinical testing This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ARSB are known to be pathogenic (PMID: 17458871, 22133300). This variant has been observed in an individual affected with mucopolysaccharidosis type VI (PMID: 23430861). ClinVar contains an entry for this variant (Variation ID: 488822). This sequence change creates a premature translational stop signal (p.Tyr251*) in the ARSB gene. It is expected to result in an absent or disrupted protein product.
CeGaT Center for Human Genetics Tuebingen RCV000579253 SCV001371503 pathogenic not provided 2020-05-01 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000677594 SCV002018863 pathogenic Mucopolysaccharidosis type 6 2021-01-13 criteria provided, single submitter clinical testing
Baylor Genetics RCV000677594 SCV004202312 pathogenic Mucopolysaccharidosis type 6 2021-12-04 criteria provided, single submitter clinical testing
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center RCV000677594 SCV005038867 pathogenic Mucopolysaccharidosis type 6 2024-03-14 criteria provided, single submitter clinical testing
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City RCV000677594 SCV001133218 pathogenic Mucopolysaccharidosis type 6 2019-09-26 no assertion criteria provided clinical testing
Natera, Inc. RCV000677594 SCV001457626 pathogenic Mucopolysaccharidosis type 6 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.